PT Kalbe Farma TbkFRA:LCLA 77 Buyback Yield % is 1.53 as of Jul. 07, 2026, which is 61% above its 10-year median of 0.95. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 291 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 86.94% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
PT Kalbe Farma Tbk Buyback Yield % Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kalbe Farma Tbk (FRA:LCLA) has a Buyback Yield % of 1.53 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PT Kalbe Farma Tbk and its competitors. This is 61% above median its historical median of 0.95. Over the past decade, PT Kalbe Farma Tbk's Buyback Yield % has ranged from 0.03 to 2.15. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #38 out of 291 companies in the Drug Manufacturers industry, placing it in the top 13.1%.
Is PT Kalbe Farma Tbk's Buyback Yield % too high?
PT Kalbe Farma Tbk's current Buyback Yield % of 1.53 is 61% above median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 2.15. Based on the distribution chart, PT Kalbe Farma Tbk ranks #38 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #38 out of 291 companies for Buyback Yield %. This places PT Kalbe Farma Tbk in the top 13% of its industry — outperforming the majority of peers. Historically, PT Kalbe Farma Tbk's own Buyback Yield % has ranged from 0.03 to 2.15 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PT Kalbe Farma Tbk and its competitors. PT Kalbe Farma Tbk's current Buyback Yield % is 1.53, which is 61% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 58.6% below its estimated fair value. The current Buyback Yield % is 1.53, which is 61% above median its 10-year median of 0.95. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Buyback Yield % is 1.53 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 58.6% below its estimated GF Value™ of €0.07.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
Buyback Yield %: 1.53 (61% above median its 10-year median of 0.95)
GF Value™: €0.07 vs. price of €0.03 (58.6% below fair value)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
